Demonstrates enhanced anti-helminth immunity in a mouse model using novel vaccine platform.
Intestinal helminth infections including Trichinella spiralis impose a heavy burden globally, yet effective oral vaccines are lacking due to antigen degradation and poor mucosal immunogenicity. This study develops an oral vaccine platform using yeast-derived β-glucan particles (GPs) to encapsulate T. spiralis antigens (Ag-GPs). These Ag-GPs demonstrated efficient antigen encapsulation, gastrointestinal stability, and excellent biocompatibility. In a mouse model, oral immunization with Ag-GPs was biocompatible and induced robust mucosal (SIgA) and systemic (IgG, IgE) antibody responses, while also stimulating dendritic cell maturation and T-cell activation. This immunization resulted in significant reductions in both adult worm and muscle larval burdens following T. spiralis challenge. Notably, the observed protective immunity strongly correlated with Dectin-1 receptor-mediated particle uptake and subsequent systemic immune activation. This work presents a promising dual-function platform, acting as both an adjuvant and delivery system, for developing oral vaccines against intestinal parasites.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: